IBS C News and Research

RSS

Genetic underpinning of placebo effect identified

US researchers have identified a gene that appears to be responsible for the placebo effect.

1 Nov 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Advances in endoscopic technologies and techniques to be highlighted at ACG annual meeting

Advances in endoscopic technologies and techniques will be highlighted in clinical research presented at the 77th Annual Scientific Meeting of the American College of Gastroenterology in Las Vegas, NV.

23 Oct 2012

Possible overlap exists between inflammatory bowel disease and IBS

Research unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas suggests a possible overlap of symptoms of two prevalent GI disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and further suggests a possible link between subtle GI tract inflammation and IBS symptoms-a link that is also the focus of the first systemic review of the literature on this topic and an editorial both published in this month's American Journal of Gastroenterology.

23 Oct 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Constipation drug may bring US patients relief

The US Food and Drug Administration has approved linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

6 Sep 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

31 Aug 2012

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

New York University College of Nursing's (NYUCN) Joyce K. Anastasi, PhD, DrNP, FAAN, LAc., the Independence Foundation Endowed Professor and Founding Director of the Division of Special Studies in Symptom Management at NYUCN has been awarded a $2.5 million four-year National Institutes of Health (NIH) grant for the study of "Symptom management for irritable bowel syndrome (IBS) constipation".

7 Aug 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Overgrowth of bacteria in the gut linked to IBS

An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold standard" method of connecting bacteria to the cause of the disease that affects an estimated 30 million people in the United States.

28 May 2012

Bacteria are key contributors to the cause of IBS, study confirms

25 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012